roquefort therapeutics plc
roquefort therapeutics plc Company Information
Company Number
12819145
Next Accounts
Jun 2025
Shareholders
stephen paul west
glenn ross whiddon
Group Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
85 great portland street, first floor, london, W1W 7LT
Website
roquefortplc.comroquefort therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ROQUEFORT THERAPEUTICS PLC at £262.2k based on a Turnover of £200k and 1.31x industry multiple (adjusted for size and gross margin).
roquefort therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ROQUEFORT THERAPEUTICS PLC at £0 based on an EBITDA of £-1.9m and a 5.17x industry multiple (adjusted for size and gross margin).
roquefort therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ROQUEFORT THERAPEUTICS PLC at £9.8m based on Net Assets of £5.5m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Roquefort Therapeutics Plc Overview
Roquefort Therapeutics Plc is a live company located in london, W1W 7LT with a Companies House number of 12819145. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in August 2020, it's largest shareholder is stephen paul west with a 50% stake. Roquefort Therapeutics Plc is a young, micro sized company, Pomanda has estimated its turnover at £200k with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Roquefort Therapeutics Plc Health Check
Pomanda's financial health check has awarded Roquefort Therapeutics Plc a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
3 Strong
1 Regular
5 Weak
Size
annual sales of £200k, make it smaller than the average company (£4.3m)
£200k - Roquefort Therapeutics Plc
£4.3m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Roquefort Therapeutics Plc
- - Industry AVG
Production
with a gross margin of 54.2%, this company has a comparable cost of product (54.2%)
54.2% - Roquefort Therapeutics Plc
54.2% - Industry AVG
Profitability
an operating margin of -964.9% make it less profitable than the average company (-5.3%)
-964.9% - Roquefort Therapeutics Plc
-5.3% - Industry AVG
Employees
with 10 employees, this is below the industry average (54)
10 - Roquefort Therapeutics Plc
54 - Industry AVG
Pay Structure
on an average salary of £108.8k, the company has a higher pay structure (£83.2k)
£108.8k - Roquefort Therapeutics Plc
£83.2k - Industry AVG
Efficiency
resulting in sales per employee of £20k, this is less efficient (£131.4k)
£20k - Roquefort Therapeutics Plc
£131.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Roquefort Therapeutics Plc
- - Industry AVG
Creditor Days
its suppliers are paid after 576 days, this is slower than average (62 days)
576 days - Roquefort Therapeutics Plc
62 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Roquefort Therapeutics Plc
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 90 weeks, this is more cash available to meet short term requirements (30 weeks)
90 weeks - Roquefort Therapeutics Plc
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 9.7%, this is a lower level of debt than the average (52.5%)
9.7% - Roquefort Therapeutics Plc
52.5% - Industry AVG
ROQUEFORT THERAPEUTICS PLC financials
Roquefort Therapeutics Plc's latest turnover from December 2023 is £200 thousand and the company has net assets of £5.5 million. According to their latest financial statements, Roquefort Therapeutics Plc has 10 employees and maintains cash reserves of £537.3 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|
| Turnover | 200,000 | 719 | |
| Other Income Or Grants | |||
| Cost Of Sales | |||
| Gross Profit | |||
| Admin Expenses | |||
| Operating Profit | -1,929,754 | -1,634,303 | -917,433 |
| Interest Payable | 58 | ||
| Interest Receivable | 1,469 | ||
| Pre-Tax Profit | -1,932,233 | -1,634,303 | -917,433 |
| Tax | 187,693 | 18,886 | |
| Profit After Tax | -1,744,540 | -1,615,417 | -917,433 |
| Dividends Paid | |||
| Retained Profit | -1,744,540 | -1,615,417 | -917,433 |
| Employee Costs | 1,087,947 | 572,538 | |
| Number Of Employees | 10 | 5 | 1 |
| EBITDA* | -1,929,754 | -1,634,303 | -917,433 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|
| Tangible Assets | 50,152 | ||
| Intangible Assets | 5,343,505 | 5,343,505 | 1,481,530 |
| Investments & Other | |||
| Debtors (Due After 1 year) | |||
| Total Fixed Assets | 5,393,657 | 5,343,505 | 1,481,530 |
| Stock & work in progress | |||
| Trade Debtors | 17,825 | ||
| Group Debtors | |||
| Misc Debtors | 157,589 | 101,738 | 2,160,958 |
| Cash | 537,322 | 2,322,974 | 899,721 |
| misc current assets | |||
| total current assets | 694,911 | 2,424,712 | 3,078,504 |
| total assets | 6,088,568 | 7,768,217 | 4,560,034 |
| Bank overdraft | |||
| Bank loan | |||
| Trade Creditors | 144,841 | 68,379 | 40,718 |
| Group/Directors Accounts | |||
| other short term finances | |||
| hp & lease commitments | |||
| other current liabilities | 162,273 | 211,291 | 154,799 |
| total current liabilities | 307,114 | 279,670 | 195,517 |
| loans | |||
| hp & lease commitments | |||
| Accruals and Deferred Income | |||
| other liabilities | |||
| provisions | 563,822 | 563,822 | 563,822 |
| total long term liabilities | 281,911 | 281,911 | 281,911 |
| total liabilities | 589,025 | 561,581 | 477,428 |
| net assets | 5,499,543 | 7,206,636 | 4,082,606 |
| total shareholders funds | 5,499,543 | 7,206,636 | 4,082,606 |
| Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|
| Operating Activities | |||
| Operating Profit | -1,929,754 | -1,634,303 | -917,433 |
| Depreciation | |||
| Amortisation | |||
| Tax | 187,693 | 18,886 | |
| Stock | |||
| Debtors | 55,851 | -2,077,045 | 2,178,783 |
| Creditors | 76,462 | 27,661 | 40,718 |
| Accruals and Deferred Income | -49,018 | 56,492 | 154,799 |
| Deferred Taxes & Provisions | 563,822 | ||
| Cash flow from operations | -1,770,468 | 545,781 | -2,336,877 |
| Investing Activities | |||
| capital expenditure | |||
| Change in Investments | |||
| cash flow from investments | |||
| Financing Activities | |||
| Bank loans | |||
| Group/Directors Accounts | |||
| Other Short Term Loans | |||
| Long term loans | |||
| Hire Purchase and Lease Commitments | |||
| other long term liabilities | |||
| share issue | |||
| interest | 1,411 | ||
| cash flow from financing | 38,858 | 4,739,447 | 5,000,039 |
| cash and cash equivalents | |||
| cash | -1,785,652 | 1,423,253 | 899,721 |
| overdraft | |||
| change in cash | -1,785,652 | 1,423,253 | 899,721 |
roquefort therapeutics plc Credit Report and Business Information
Roquefort Therapeutics Plc Competitor Analysis
Perform a competitor analysis for roquefort therapeutics plc by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in W1W area or any other competitors across 12 key performance metrics.
roquefort therapeutics plc Ownership
ROQUEFORT THERAPEUTICS PLC group structure
Roquefort Therapeutics Plc has no subsidiary companies.
Ultimate parent company
ROQUEFORT THERAPEUTICS PLC
12819145
roquefort therapeutics plc directors
Roquefort Therapeutics Plc currently has 6 directors. The longest serving directors include Mr Stephen West (Aug 2020) and Ms Jean Duvall (Apr 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Stephen West | 52 years | Aug 2020 | - | Director | |
| Ms Jean Duvall | England | 63 years | Apr 2022 | - | Director |
| Dr Simon Sinclair | England | 52 years | Apr 2022 | - | Director |
| Dr Darrin Disley | England | 57 years | Sep 2022 | - | Director |
| Mr Trevor Reginald | England | 53 years | Sep 2022 | - | Director |
| Sir Martin Evans | England | 84 years | Sep 2022 | - | Director |
P&L
December 2023turnover
200k
0%
operating profit
-1.9m
+18%
gross margin
54.2%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
5.5m
-0.24%
total assets
6.1m
-0.22%
cash
537.3k
-0.77%
net assets
Total assets minus all liabilities
Similar Companies
roquefort therapeutics plc company details
company number
12819145
Type
Public limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
August 2020
age
5
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
December 2023
previous names
roquefort investments plc (December 2021)
accountant
-
auditor
RPG CROUCH CHAPMAN LLP
address
85 great portland street, first floor, london, W1W 7LT
Bank
HSBC BANK PLC
Legal Advisor
RPC
roquefort therapeutics plc Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to roquefort therapeutics plc.
roquefort therapeutics plc Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ROQUEFORT THERAPEUTICS PLC. This can take several minutes, an email will notify you when this has completed.
roquefort therapeutics plc Companies House Filings - See Documents
| date | description | view/download |
|---|
